Biolegend, 938903, Ultra-LEAF™ Purified anti-mouse CX3CL1 (Fractalkine) Antibody, 100μg

CX3CL1 is a unique chemokine subclass, synthesized as a transmembrane molecule. It consists of an extracellular NH2-terminal domain, a mucin-like stalk, a transmembrane α helix, and a short cytoplasmic tail. CX3CL1 exists in two forms: as a membrane-anchored or as a shed 80-95K glycoprotein. Soluble CX3CL1 is generated by limited proteolysis on the cell surface, and a disintegrin and metallopeptidase 10 (ADAM10) and ADAM17/tumor necrosis factor-α-converting enzyme (ADAM17/TACE) participate in this shedding. It has been suggested that ADAM10 acts in the constitutive shedding, and ADAM17 acts in response to cell activation. CX3CL1 is associated with the development of different diseases such as rheumatoid arthritis (RA), rheumatoid vasculitis (RV), Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), scleroderma, multiple sclerosis, and atherosclerosis. Soluble fractalkine has been detected in the cerebrospinal fluid of patients with neuropsychiatric lupus, and is present at higher levels in the serum of patients with SS, RA, and type 2 diabetes than in control subjects.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant mouse CX3CL1 (Fractalkine)
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Neut - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by neutralization of the chemotaxis induced by recombinant mouse CX3CL1 (Fractalkine) on mouse Baf3-mCX3CR1 transfectant chemoattractant cells. ND50 range: 2-10 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
Product Citations: Zhang C, et al. 2024. Nat Commun. 7077:15. PubMed
RRID: AB_2894524 (BioLegend Cat. No. 938903) AB_2894524 (BioLegend Cat. No. 938904)
Structure: Chemokine
Distribution: Microglia, endothelial cells, fibroblasts, neuronal cells, hepatocytes, smooth muscle cells, monocytes, adipocytes, and human astrocytes stimulated by TNF-α and IFN-γ. CX3CL1 is also expressed in macrophages, fibroblasts, endothelial, and dendritic cells in RA synovial tissue
Function: CX3CL1 has potent chemoattractant activity for T cells, monocytes, and natural killer cells, and the expression of CX3CL1 in activated endothelial cells promotes strong adhesion of those leukocytes. CXC3L1 is induced in endothelial cells by proinflammatory cytokines (TNF-α, IFN-γ, IL-1β) and LPS.
Interaction: Monocytic cells, smooth muscle cells, T cells, B lymphocytes, NK cells, microglia, and astrocytes
Ligand/Receptor: CX3CR1
Cell Type: B cells, Endothelial cells, Microglia
Biology Area: Cell Biology, Neuroscience, Signal Transduction
Molecular Family: Cytokines/Chemokines
Antigen References: Bazan JF, et al. 1997. Nature. 385:640. Hundhausen C, et al. 2003. Blood. 102:1186. Sato E, et al. 2006. Ann Rheum Dis. 65:1257. Hundhausen C, et al. 2007 J Immunol. 178:8064. Jones B, et al. 2011. Front Immunol. 2:82. Hamann I, et al. 2011. Immunology. 133:62. Shah R, et al. 2011. Diabetes. 60:1512.
Gene ID: 20312
UniProt: View information about CX3CL1 on UniProt.org
Clone: A19080D
Regulatory Status: RUO
Other Names: Small inducible cytokine subfamily D, member 1 (SCYD1), Neurotactin (NTT, NTN)
Isotype: Rat IgG2b, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.